In addition to TP53 disruption, these investigations have to take into account other recurrent CLL mutations with an emphasis on telomeres, such as altered ATM and SF3B1 genes and, as stated above, the POT1 gene. This evidence concerns the gene POT1 and B-cell chronic lymphocytic leukemia.